| Name | Title | Contact Details |
|---|
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Perseon Corporation invests its resources in fighting humanity`s worst disease: cancer. Perseon`s people are dedicated to finding innovative technologies and means to deliver energy solutions to healthcare providers and patients around the world. MicroThermX® treats soft tissue tumors with precision-focused energy, expanding the options and broadening the opportunities for cancer treatment.
Sorenson BioScience is a manufacturer of disposable plastic liquid handling products. Located in Salt Lake City, Utah, it was founded in 1981 as Mµlti Technology, Inc. The company rapidly became an innovator in the manufacture of liquid handling products
McFarlane Medical is a Geneva, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Colorado Serum Company is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.